Q-omics provides the consensus-scored HMGA1P6 profile across patient tissues and cancer cell-line models. HMGA1P6 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, HMGA1P6 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, HMGA1P6 RNA expression shows 5,088 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight LIHC, COAD, and KIRC as cancer lineages where HMGA1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGA1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGA1P6 survival associations across molecular data types. HMGA1P6 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGA1P6 RNA expression–survival associations across cancer types. High HMGA1P6 expression shows unfavorable associations in LIHC, PAAD, UCEC, TGCT, BLCA and MESO. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for HMGA1P6 RNA expression.
This table summarizes HMGA1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for HMGA1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGA1P6 shows higher tumor expression in COAD, LUSC, LUAD and STAD. The COAD box plot shows higher HMGA1P6 RNA expression in tumor versus normal tissue (log2 FC = +0.135, t-test p = .002).
This table shows molecular features associated with HMGA1P6 in patient tissues and cancer cell lines. In patient samples, HMGA1P6 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
